iTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025
iTeos Therapeutics, Inc. (NASDAQ: ITOS) had its price target lowered by analysts at Wells Fargo & Company from $19.00 to $17.00. They now have an "overweight" rating on the stock.
iTeos Therapeutics, Inc. (NASDAQ: ITOS) had its price target lowered by analysts at JPMorgan Chase & Co. from $22.00 to $15.00. They now have an "overweight" rating on the stock.
iTeos Therapeutics, Inc. (NASDAQ: ITOS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $46.00 price target on the stock.
iTeos Therapeutics, Inc. (NASDAQ: ITOS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $25.00 price target on the stock.